Street Talk

Carlyle chases potential four-bagger at biotech Opthea

Anthony Macdonald, Sarah Thompson and Kanika Sood

Aug 11, 2022 – 9.33pm

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

The Carlyle Group and its newly acquired life sciences arm Abingworth are seeking to make up to four-times their money at Australian eye therapies developer Opthea.

As Street Talk revealed on Thursday morning, Carlyle/ABW will tip up to $US170 million ($242 million) into Opthea in a bid to get the company’s lead therapeutic candidate OPT-302 to market.

Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies.

Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.

Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.